Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

NCT ID: NCT01532076

Last Updated: 2014-09-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2014-09-30

Brief Summary

Failure rates of up to 30% are reported after proximal humeral fractures despite angular-stable devices. This may devastate not only the functional outcome but also the independence of elderly patients.

To increase bone mineral density and thereby holding-strength augmentation is an option. Autologous bone-graft, as current gold-standard, though is questionable in osteoporosis since osteoprogenitors are dysfunctional and the harvesting-morbidity considerable. Adipose tissue seems an alternative cell-source even in presence of osteoporosis.

Stromal vascular fraction (SVF) cells isolated from lipoaspirates display osteogenic and vasculogenic potential and can be harvested in high numbers. Expansion associated with costly good-manufacturers-practice facilities is avoidable, so are repeated interventions. These cells have been successfully used to generate osteogenic composite grafts with intrinsic vascularity in preclinical models.

For translation into clinical practice after a 20 patient external pilot a prospective randomized controlled trial with 270 patients is planned. For the trial lipoaspiration precedes open reduction and internal fixation in individuals over 60 years presenting with a proximal humeral fracture after low-energy trauma. Cells are isolated (Cellution®800/CRS) and wrapped around hydroxyapatite microgranules after embedding in a fibrin-gel for augmentation of the typical bone-void. Clinical/radiological follow-up is at 6 and 12 weeks for immediate complications and after 6, 9 and 12 months. Functional assessment is performed after 6 weeks, 6 and 12 months using the Quick-Dash- and Constant-Score.

The primary outcome is a reduction in secondary dislocation by 50% during the first postoperative year. Secondary dislocation is diagnosed on plain radiographs by an independent board certified radiologist specialised in musculoskeletal imaging if one or more of the following criteria are met:

• More than 20° varus collapse of the humeral head fragment in relation to the humeral shaft
• Screw penetration through the humeral head

Conditions

Osteoporotic Fractures

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

cellularized composite graft augmentation

lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;

Group Type: EXPERIMENTAL

Cellularized composite graft augmentation

Intervention Type: PROCEDURE

liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules

Control acellular composite graft augmentation

open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.

Group Type: ACTIVE_COMPARATOR

Acellular composite graft augmentation

Intervention Type: PROCEDURE

Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite

Interventions

Cellularized composite graft augmentation

liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules

Intervention Type: PROCEDURE

Acellular composite graft augmentation

Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite

Intervention Type: PROCEDURE

Other Intervention Names

Cellution/CR800, Cytori, US; Tisseel, Baxter, Germany; Actifuse Microgranules, Apatech, Germany; Tisseel, Baxter, Germany; Actifuse Microgranules, Apatech, Germany

Eligibility Criteria

Inclusion Criteria

Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:

• indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma

• displacement of more than 1 cm between fragments and/or
• angulation of 45° or more between the fragments and/or
• dislocation of the greater tuberosity of 5 mm or more and/or
• patient specific factors like high functional demand etc
• age > 50 years
• postmenopausal status (i.e. 12 continuous month without menstruation)
• informed consent in surgery and study participation

Exclusion Criteria

• Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) <24, schizophrenia, major depression)
• Pathological fractures caused by other conditions
• Fracture-related nerve injury
• Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)
• BMI <20 kg/m2
• Known hypersensitivity to one of the graft components
• Participation in a clinical trial within 3 month before enrolment

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Basel, Switzerland

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Franziska Saxer, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Marcel Jakob, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Locations

University Hospital Basel

Basel, Canton of Basel-City, Switzerland

Countries

Switzerland

References

Handoll HH, Elliott J, Thillemann TM, Aluko P, Brorson S. Interventions for treating proximal humeral fractures in adults. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD000434. doi: 10.1002/14651858.CD000434.pub5.

Reference Type: DERIVED

PMID: 35727196 (View on PubMed)

Other Identifiers

348/10

Identifier Type: -

Identifier Source: org_study_id